| Date | Time | Source | Headline | Symbol | Company |
| 05/09/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Participate in Two Investor Conferences in May | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 05/08/2023 | 4:07PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 05/08/2023 | 4:01PM | Business Wire | Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 05/08/2023 | 4:01PM | Business Wire | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 05/02/2023 | 4:01PM | Business Wire | Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/25/2023 | 8:01AM | Business Wire | Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/19/2023 | 7:26PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/17/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/06/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/05/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 03/14/2023 | 6:26PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 03/14/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 03/10/2023 | 4:44PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 03/08/2023 | 8:51AM | Business Wire | Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 03/07/2023 | 4:01PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 03/07/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 03/06/2023 | 5:20PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 03/06/2023 | 5:19PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 03/06/2023 | 5:17PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 03/06/2023 | 5:16PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/14/2023 | 2:32PM | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/14/2023 | 12:44PM | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/09/2023 | 11:28AM | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/08/2023 | 4:07PM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/08/2023 | 1:17PM | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/07/2023 | 4:07PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/07/2023 | 4:01PM | Business Wire | Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/07/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/06/2023 | 9:09AM | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 01/31/2023 | 3:18PM | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |